Showing 191-200 of 3354 results for "".
- App Launched for Medical Entrepreneurshttps://practicaldermatology.com/news/20120824-app_launched_for_medical_entrepreneurs/2459746/The free Medical Entrepreneur App went live on the Apple Store this month. The app, developed by Steven M. Hacker, MD, provides healthcare providers and medical students with business intelligence and decision making tools before, duri
- Nickel Reactions on the Rise. Diet to Blame?https://practicaldermatology.com/news/20120302-nickel_reactions_on_the_rise_diet_to_blame/2459857/Certain patients consuming healthy diets consisting of whole grains, legumes, nuts, and soy may be at increased risk of developing allergic reactions to nickel, according to dermatologist Matthew Zirwas, MD, an associate professor at
- The American Society for Laser Medicine and Surgery Names New Officershttps://practicaldermatology.com/news/the-american-society-for-laser-medicine-and-surgery-names-new-officers/2458185/The American Society for Laser Medicine and Surgery (ASLMS) introduced Mathew M. Avram, MD, JD, as its new President at the Annual Conference in April. Dr. Avram succeeds Kristen M. Kelly, MD, who now serves as the Society’s Past President. The 2017-18 ASLMS Executive Committee also i
- Dr. Alexa Kimball Highlights Early Response, HiSCR75 Findings With Tulisokibart in Hidradenitis Suppurativahttps://practicaldermatology.com/news/dr-alexa-kimball-highlights-early-response-hiscr75-findings-with-tulisokibart-in-hidradenitis-suppurativa/2488609/New Phase 2b data for tulisokibart may provide early clinical evidence supporting tumor necrosis factor-like cytokine 1A (TL1A) as a therapeutic target in hidradenitis suppurativa (HS), according to study investigator Alexa Kimball, MD, MPH.
- From SCALE 2026: Practical Strategies for Treating GLP-1–Related Aesthetic Changeshttps://practicaldermatology.com/news/from-scale-2026-practical-strategies-for-treating-glp-1related-aesthetic-changes/2487118/At the 2026 Music City SCALE meeting, Terrence Keaney, MD, discussed how dermatologists can proactively address facial aging, skin laxity, hair loss, and muscle loss associated with GLP-1–mediated weight reduction, outlining a practical framework for managing some of the aesthetic issues related
- From SCALE 2026: Dermatologists Navigate the Expanding Role of GLP-1s in Skin Health and Aesthetic Carehttps://practicaldermatology.com/news/dermatologists-navigate-the-expanding-role-of-glp-1s-in-skin-health-and-aesthetic-care/2487095/As use of GLP-1 receptor agonists continues to surge, dermatologists are increasingly encountering the downstream effects of these medications in both medical and cosmetic practice. During a session at the 2026 Music City SCALE meeting in Nashville, dermatologist and researcher Glynis Ablon, MD,
- Dr. Lisa Swanson Presents on Communication, Therapeutics, and Confidence in Treating Children at Noahhttps://practicaldermatology.com/news/dr-lisa-swanson-presents-on-communication-therapeutics-and-confidence-in-treating-children-at-noah/2486876/At the 67th Noah Worcester Dermatological Society Annual Meeting, Practical Dermatology Associate Medical Editor Lisa Swanson, MD, FAAD, delivered the Alfred L. Weiner Lecture titled “Afraid to Treat Kids? Here are some Pearls to Help!” The session focused on practical, clinic-ready stra
- Rademikibart Shows High Long-Term Efficacy in Atopic Dermatitishttps://practicaldermatology.com/news/rademikibart-shows-high-long-term-efficacy-in-atopic-dermatitis/2486495/Rademikibart, a next-generation anti–IL-4 receptor alpha monoclonal antibody, demonstrated robust and sustained efficacy in moderate-to-severe atopic dermatitis (AD) through 52 weeks, according to Phase 3 RADIANT-AD data presented by Cheng Zhou, MD, at the American Academy of Dermatology (AAD) 20
- Nemolizumab Shows Efficacy in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/nemolizumab-shows-efficacy-in-pediatric-atopic-dermatitis/2486457/Nemolizumab, an IL-31 receptor alpha (IL-31Rα) antagonist, demonstrated favorable pharmacokinetics, sustained efficacy, and a consistent safety profile in children aged 2 to 11 years with moderate-to-severe atopic dermatitis (AD), according to Phase 2 data presented by Linda Stein Gold, MD, at th
- Upadacitinib Shows Strong Hair Regrowth in Alopecia Areatahttps://practicaldermatology.com/news/upadacitinib-shows-strong-hair-regrowth-in-alopecia-areata/2486456/Upadacitinib demonstrated robust efficacy in both adolescents and adults with severe alopecia areata (AA), with particularly strong responses observed in younger patients, according to a subgroup analysis of two Phase 3 trials presented by Melinda Gooderham, MD, MSc, at the American Academy of De